Use of Erythromycin in Mustard-Induced Bronchiolitis

Sponsor

Baqiyatallah Medical Sciences University (Other)

Overall Status

Completed

CT.gov ID

NCT00367419

Collaborator

(none)

Location

Study Details

We looked for the effectiveness of low-dose long-term prescription of erythromycin in mustard-induced bronchiolitis obliterans

Condition or Disease	Intervention/Treatment	Phase
Bronchiolitis Obliterans Acute Obliterating Bronchiolitis	Drug: Erythromycin	Phase 4

Study Type:

Interventional

Allocation:

Randomized

Intervention Model:

Single Group Assignment

Masking:

Double

Primary Purpose:

Treatment

Official Title:

Low-Dose Long-Term Prescription of Erythromycin in Mustard-Induced Bronchiolitis Obliterans

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

Male

Documented chemical exposure
Clinical, spirometric and radiological findings were compatible with BO on High Resolution Computed Tomography (HRCT)
Non-responsiveness to high dose bronchodilator therapy

Radiographic evidence of pneumonia, active tuberculosis, lung carcinoma, or an infection that necessitated the use of an antibiotic
History of cigarette smoking and occupational exposure to toxic agents of hypersensitivity to macrolides
History of treatment with a systemic antibiotic within 7 days before the start of the study
Any investigational medicine within 4 weeks of the study
History of antibiotic injection within 6 weeks before the study
Concomitant Theophylline or Carbamazepine, unless their serum concentrations were regularly monitored
Patients who were in the exacerbation phase of their respiratory complications
Need to use medications interact with macrolides such as Digoxin, Theophylline and Carbamazepine
Systemic antibiotics
Systemic Corticosteroids
Admission to the hospital
Abnormal kidney or liver function